Real World Use of Tocilizumab Biosimilar studY
This study is called 'Real World Use of Tocilizumab Biosimilar study' and is looking at how a medicine called Tyenne, which is a 'biosimilar' version of an existing drug, works for people with rheumatoid arthritis (RA). It's not a trial where you're given a new treatment to test, but rather observes people who are already prescribed Tyenne by their doctor. The main goal is to see how long patients continue taking Tyenne over 6 and 12 months in their normal lives, outside of a strict clinical trial setting. Researchers will follow patients for a year, collecting information during their regular clinic visits.
At a glance
What is this study about?
This study is about a medicine called Tyenne, which is used to treat rheumatoid arthritis (RA). RA is a long-term condition that causes pain, swelling, and stiffness in the joints. Tyenne is a 'biosimilar' medicine. This means it's very much like an existing medicine called tocilizumab, but it's made by a different company. Think of it like different brands of a similar product – they work in the same way.
Unlike traditional clinical trials where people might be given a new medicine or a placebo (a dummy treatment), this study simply observes what happens when doctors prescribe Tyenne to their patients in the usual way. The decision for you to take Tyenne would be made by your doctor based on what's best for your condition, before you even consider joining this study. So, joining this study doesn't change your medical treatment plan.
The main thing the researchers want to find out is how long people continue to take Tyenne. They'll be looking at this after 6 months and again after 12 months. This kind of 'real-world' information is very useful for doctors and healthcare providers to understand how well a new medicine fits into patients' lives and their treatment journey.
Key takeaways
- This study observes real-world use of Tyenne, a medicine for rheumatoid arthritis (RA).
- It aims to understand how long patients stay on Tyenne treatment.
- Your doctor decides your treatment before you join; the study doesn't change it.
- Participation involves sharing information from your routine clinic visits for up to 12 months.
- You must have moderate to severe RA and be able to give informed consent.
Who may be eligible?
To join this study, you need to have been diagnosed with moderate to severe rheumatoid arthritis. Your doctor must have already decided that Tyenne is the right treatment for you, following their usual practice and based on current medical guidelines.
You also need to be able to fill out study questionnaires in English or your local language. Most importantly, you must be willing to take part and give your written permission (called informed consent) to join the study.
If you are currently taking part in another clinical trial that involves a new medicine or treatment, you wouldn't be able to join this study. This helps make sure the information collected is clear and isn't affected by other experimental treatments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do you have a diagnosis of moderate to severe rheumatoid arthritis?
- Has your doctor already decided to prescribe you Tyenne?
- Are you able to understand and complete questionnaires?
- Are you willing to sign a consent form to join?
- Are you *not* currently in another clinical trial for an experimental treatment?
What does participation involve?
If you decide to take part, your doctor will have already prescribed you Tyenne for your rheumatoid arthritis. You'll be followed for 12 months, or until you stop taking Tyenne permanently. You'll have one initial visit when you start the study and then three follow-up visits, typically around 3, 6, and 12 months after you begin Tyenne.
All of these follow-up visits will be your regular clinic appointments with your doctor. The study won't add extra appointments to your schedule; it will just use information gathered during your routine care. During these visits, you might be asked to complete some questionnaires. The total time you'd be involved in the study is up to 12 months.
Potential risks and benefits
Locations (8)
- Rheumatologische Schwerpunktpraxis BerlinVerified postcodeBerlin, Germany
- Rheumapraxis Dr. Liebhaber HalleVerified postcodeHalle, Germany
- Facharztpraxis für Innere Medizin LudwigsfeldeVerified postcodeLudwigsfelde, Germany
- Rheumatologische FacharztpraxisVerified postcodeMagdeburg, Germany
- Facharztpraxis für Innere MedizinVerified postcodeNaumburg, Germany
- Klinische ForschungVerified postcodePlanegg, Germany
- Rheumahaus PotsdamVerified postcodePotsdam, Germany
- Rheumatologische Facharztpraxis TemplinVerified postcodeTemplin, Germany
Common questions
What is rheumatoid arthritis?
Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints, often affecting the hands and feet.
What is a 'biosimilar' medicine?
A biosimilar is a medicine that is very similar to an existing approved medicine, working in the same way to treat your condition.
Will I be given Tyenne if I join this study?
No, your doctor will have already decided to prescribe you Tyenne before you consider joining the study. The study observes this real-life use.
How long will I be in the study?
You'll be part of the study for up to 12 months, or until you permanently stop taking Tyenne.
Will I have extra doctor's appointments?
No, the study will collect information during your regular, planned clinic visits with your doctor.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.